UBS Maintains Neutral on Pediatrix Medical Group, Raises Price Target to $10.5
Portfolio Pulse from Benzinga Newsdesk
UBS analyst A.J. Rice maintains a Neutral rating on Pediatrix Medical Group (NYSE:MD) and raises the price target from $9 to $10.5.

August 09, 2024 | 2:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UBS analyst A.J. Rice maintains a Neutral rating on Pediatrix Medical Group and raises the price target from $9 to $10.5.
The raised price target from $9 to $10.5 suggests a positive outlook, which could lead to a short-term increase in stock price. However, the Neutral rating indicates that the stock may not outperform the market significantly.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100